Skip to content

Vera Therapeutics

US · VERA #2739 by market cap Listed 2021
25.45 -1.30 -4.86%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

Pre-market 26.34 -1.53%
After-hours 24.88 -2.24%
43.1525.4525.452026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on VERA?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is -13.6% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has risen to 16.8% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days D → D

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 02:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall C-

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability D-

How much profit the business keeps from each dollar of sales and capital.

Return on equity -50.7% Better than 9%
Return on invested capital -48.2% Better than 6%
Momentum D+

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -21.1% Better than 29%
6-month return -25.2% Better than 22%
12-month return (ex latest month) -1.7% Better than 32%
Distance below 52-week high 54.6% Better than 15%
Financial Health B

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 13.6x Better than 96%
Debt to assets 10.5% Better than 69%
Interest coverage -38.8x Better than 8%
Analyst View A

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 83.3% Better than 63%
Upside to average target 175.8% Better than 93%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -9.43%
1M -15.34%
3M -18.59%
6M -26.49%
YTD -49.74%
1Y -8.68%
3Y +88.52%
5Y -18.43%

Key statistics

Price & volume

Prev close
26.75
Open
26.37
Day range
25.16 - 27.15
Avg price
25.75
Volume
1.37M
Turnover
35.35M
Amplitude
7.44%
52-week range
25.08 - 56.05

Valuation

P/E
-5.46
P/E (TTM)
-4.31
P/B
5.52
EPS
-4.66
Net profit
-336.91M
Net assets
333.15M

Share structure

Market cap
1.84B
Float cap
1.25B
Shares out
72.30M
Float shares
49.29M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2021-05-14
52-week range 1% of range
25.08 56.05

54.6% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-2.51M net over the window

Short interest

Shares short
12.14M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Vera Therapeutics (VERA)?

Vera Therapeutics last traded at 25.45. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Vera Therapeutics's market cap?

About 1.84B.

What is the P/E ratio of Vera Therapeutics?

The trailing twelve-month P/E is -4.31. The Valuation tab shows it against the stock's own five-year range.

Does Vera Therapeutics pay a dividend?

Vera Therapeutics does not currently pay a regular dividend.

Is Vera Therapeutics a buy according to analysts?

The consensus of 12 analysts is a Buy rating, with an average 12-month price target of 70.20, which implies 175.8% upside from the current price. This is not investment advice.

What is Vera Therapeutics's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Vera Therapeutics a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.

Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.

Vera Therapeutics discussion 0 comments

Add a comment